Skip to main content

Table 4 Effects of tofogliflozin on brachial-ankle pulse wave velocity analyzed using covariance models

From: Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

  Tofogliflozin treatment group Conventional treatment group Treatment effect (tofogliflozin–conventional treatment) (mean change [95% CI])
Right baPWV (cm/s) (mean change; SE)  
 Week 52 (n = 138) 1.3 (39.9) 77.0 (38.8) − 75.5 (− 171.1, 19.7), p = 0.12
 Week 104 (n = 130) − 67.9 (32.5) 34.7 (31.5) − 102.7 (− 182.1, − 23.2), p = 0.012
Left baPWV (cm/s) (mean change; SE)  
 Week 52 (n = 138) − 7.1 (40.1) 76.2 (39.1) − 83.3 (− 179.3, 12.8), p = 0.09
 Week 104 (n = 130) − 33.7 (32.2) 67.6 (31.4) − 101.3 (− 180.3, − 22.3), p = 0.012
Mean baPWV (cm/s) (mean change; SE)  
 Week 52 (n = 138) − 4.2 (39.2) 76.9 (38.1) − 81.2 (− 174.9, 12.6), p = 0.09
 Week 104 (n = 130) − 51.9 (31.4) 51.2 (30.5) − 103.1 (− 180.1, − 26.2), p = 0.009
  1. Differences in delta change in baPWV from the baseline between the two groups were analyzed using analysis of covariance models that included treatment group, age, sex, use of insulin, baseline mean baPWV, systolic blood pressure, presence of hypertension, and antihypertensive drug administration